Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 2/20 | 0.59 |
| ▸ | MDM4 | O15151 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 2/20 | 0.58 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.56 |
| ▸ | CASP3 | P42574 | 2/20 | 0.55 |
| ▸ | TNF | P01375 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29398908 | 1.00 | TLR2 (0.59) | TLR2MDM4TP53MDM2CASP3 | |
| SCHEMBL119530 | 1.00 | TLR2 (0.59) | TLR2MDM4TP53MDM2CASP3 | |
| SCHEMBL7532853 | 1.00 | TLR2 (0.59) | TLR2MDM4TP53MDM2CASP3 | |
| SCHEMBL29400620 | 1.00 | TLR2 (0.59) | TLR2MDM4TP53MDM2CASP3 | |
| SCHEMBL30291728 | 1.00 | TLR2 (0.59) | TLR2MDM4TP53MDM2CASP3 | |
| SCHEMBL120255 | 1.00 | TLR2 (0.59) | TLR2MDM4TP53MDM2CASP3 | |
| SCHEMBL1044856 | 0.93 | TLR2 (0.62) | TLR2MDM4TP53MDM2CASP3 | |
| SCHEMBL7420121 | 0.93 | TLR2 (0.62) | TLR2MDM4TP53MDM2CASP3 | |
| SCHEMBL29382791 | 0.93 | TLR2 (0.62) | TLR2MDM4TP53MDM2CASP3 | |
| SCHEMBL1000115 | 0.93 | TLR2 (0.62) | TLR2MDM4TP53MDM2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240218021-A1 | CYCLIN INHIBITORS | CIRCLE PHARMA, INC. | 2024-07-04 | — | — | US | disclosed |
| CN-112794917-B | Polypeptide imaging probe and preparation method and application thereof | 国家纳米科学中心 | 2022-08-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240218021-A1 | CYCLIN INHIBITORS | CCNI, CCNC, CDK2 | TLR2 4837/4885MDM4 1200/4885TP53 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.